Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells

International Journal of Cancer

Volumn 104, Issue 1, 2003, Pages 19-27

  Thomas, Christopher Y ^a,f   Chouinard, Michael ^a,d   Cox, Michael ^b,e   Parsons, Sarah ^b   Stallings Mann, Melody ^a   Garcia, Roy ^c   Jove, Richard ^c   Wharen, Robert ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e JACK BELL RESEARCH CENTRE   (Canada)

^f UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Mitogen activated protein kinases; Receptor protein tyrosine kinases

Indexed keywords

4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; CBL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GROWTH FACTOR; HEREGULIN 3; HEREGULIN 4; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPEPTIDE; PROTEIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; CELL GROWTH; CELL LINE; CELL STRAIN SKMG 3; CONTROLLED STUDY; DNA PROTEIN COMPLEX; GENE AMPLIFICATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; MALIGNANT TRANSFORMATION; PEPTIDE MAPPING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CELLS, CULTURED; DNA-BINDING PROTEINS; ENZYME ACTIVATION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; GENES, ERBB-2; GLIOBLASTOMA; HUMANS; LARYNGEAL NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM PROTEINS; NEUROGLIA; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; UBIQUITIN-PROTEIN LIGASES;

EID: 0037430199     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10880     Document Type: Article

References (60)

1. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991;51:2164-72.
2. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 1987;84:6899-903.
3. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985;313:144-7.
4. Meyer S, Labudda K, McGlade J, Hayman MJ. Analysis of the role of the Shc and Grb2 proteins in signal transduction by the v-ErbB protein. Mol Cell Biol 1994;14:3253-62.
5. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994;91:7727-31.
6. Montgomery RB, Moscatello DK, Wong AJ, Cooper JA, Stahl WL. Differential modulation of mitogen-activated protein (MAP) kinase extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor. J Biol Chem 1995;270: 30562-6.
7. Batra SK, Castelinoprabhu S, Wikstrand CJ, Zhu XP, Humphrey PA, Friedman HS, Bigner DD. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 1995;6:1251-9.
8. Masui H, Wells A, Lazar CS, Rosenfeld MG, Gill GN. Enhanced tumorigenesis of NR6 cells which express non-downregulating epidermal growth factor receptors. Cancer Res 1991;51:6170-5.
9. Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Collins VP, James CD, Liu L. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 1994;9:2313-20.
10. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, Cavenee WK. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997;272:2927-35.
11. Carter TH, Kung HJ. Tissue-specific transformation by oncogenic mutants of epidermal growth factor receptor. Crit Rev Oncogen 1994; 5:389-428.
12. Moghal N, Sternberg PW. Multiple positive and negative regulators of signaling by the EGF-receptor. Curr Opin Cell Biol 1999;11:190-6.
13. Mishima K, Higashiyama S, Asai A, Yamaoka K, Nagashima Y, Taniguchi N, Kitanaka C, Kirino T, Kuchino Y. Heparin-binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas. Acta Neuropathol 1998;96:322-8.
14. Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails. Proc Natl Acad Sci USA 1992;89:4309-13.
15. Wells A, Welsh JB, Lazar CS, Wiley HS, Gill GN, Rosenfeld MG. Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science 1990;247:962-4.
16. Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJ. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996;56:5079-86.
17. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992;89:2965-9.
18. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Nad Acad Sci USA 1998;95:5724-9.
19. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol 2000;10:147-54.
20. Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, Cavenee WK, Huang HS. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 1996;271:25639-45.
21. Wu CJ, Qian X, O'Rourke DM. Sustained mitogen-activated protein kinase activation is induced by transforming erbB receptor complexes. DNA Cell Biol 1999;18:731-41.
22. Feldkamp MM, Lala P, Lau N, Roncari L, Guha A. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 1999;45:1442-53.
23. Boerner JL, McManus MJ, Martin GS, Maihle NJ. Ras-independent oncogenic transformation by an EGF-receptor mutant. J Cell Sci 2000;113:935-42.
24. Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 1998;273:200-6.
25. Rodrigues GA, Falasca M, Zhang Z, Ong SH, Schlessinger J. A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling. Mol Cell Biol 2000;20:1448-59.
26. van Dijk M, Muriana FJ, Der Hoeven PC, de Widt J, Schaap D, Moolenaar WH, van Blitterswijk WJ. Diacylglycerol generated by exogenous phospholipase C activates the mitogen-activated protein kinase pathway independent of Ras- and phorbol ester-sensitive protein kinase C: dependence on protein kinase C-zeta. Biochem J 1997;323:693-9.
27. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, Bigner DD. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990;50:8017-22.
28. Filmus J, Pollak MN, Cairncross JG, Buick RN. Amplified, overexpressed and rearranged epidermal growth factor receptor gene in a human astrocytoma cell line. Biochem Biophys Res Comm 1985;131:207-15.
29. Thomas C, Ely G, James CD, Jenkins R, Kastan M, Jedlicka A, Burger P, Wharen R. Glioblastoma-related gene mutations and overexpression of functional epidermal growth factor receptors in SKMG-3 glioma cells. Acta Neuropathol (Berl) 2001;101:605-15.
30. Rewcastle GW, Murray DK, Elliott WL, Fry DW, Howard CT, Nelson JM, Roberts BJ, Vincent PW, Showalter HDH, Winters RT, Denny WA. Tyrosine kinase inhibitors - 14 - structure-activity relationships for methylamino-substituted derivatives of 4-[3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. J Med Chem 1998;41:742-51.
31. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons, SJ. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 1999;274:8335-43.
32. Garcia R, Yu CL, Hudnall A, Catlett R, Nelson KL. Smithgall T, Ethier SP, Jove R. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 1997;8:1267-76.
33. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984;309:418-25.
34. Merlino GT, Xu YH, Ishii S, Clark AJ, Semba K, Toyoshima K, Yamamoto T, Pastan I. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science 1984;224:417-9.
35. Lill NL, Douillard P, Awwad RA, Ota S, Lupher MLJ, Miyake S, Meissner-Lula N, Hsu VW, Band H. The evolutionarily conserved N-terminal region of Cb1 is sufficient to enhance down-regulation of the epidermal growth factor receptor. J Biol Chem 2000;275:367-77.
36. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Geiger B, Yarden Y. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 1998;12:3663-74.
37. Sorkin A, Waters CM. Endocytosis of growth factor receptors. Bioessays 1993;15:375-82.
38. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995;82:241-50.
39. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
40. Schlegel J, Stumm G, Brandle K, Merdes A, Mechtersheimer G, Hynes NE, Kiessling M. Amplification and differential expression of members of the erbB-gene family in human glioblastoma. J Neurooncol 1994;22:201-7.
41. Weiss FU, Wallasch C, Campiglio M, Issing W, Ullrich A. Distinct characteristics of heregulin signals mediated by HER3 or HER4. J Cell Physiol 1997;173:187-95.
42. Zhang K, Sun J, Liu N, Wen D, Chang D, Thomason A, Yoshinaga SK. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem 1996;271:3884-90.
43. Fitzpatrick VD, Pisacane PI, Vandlen RL, Sliwkowski MX. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4. FEBS Lett 1998; 431:102-6.
44. Culouscou JM, Carlton GW, Aruffo A. HER4 receptor activation and phosphorylation of Shc proteins by recombinant heregulin-Fc fusion proteins. J Biol Chem 1995;270:12857-63.
45. Fry DW, Nelson JM, Slintak V, Keller PR, Rewcastle GW, Denny WA, Zhou H, Bridges AJ. Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochem Pharmacol 1997;54:877-87.
46. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995;267:1782-8.
47. Osherov N, Gazit A, Gilon C, Levitzki A. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. J Biol Chem 1993;268:11134-42.
48. Wakeling AE, Barker AJ, Davies DH, Brown DS, Green LR, Cartlidge SA, Woodburn JR. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat 1996;38:67-73.
49. Heisermann GJ, Gill GN. Epidermal growth factor receptor threonine and serine residues phosphorylated in vivo. J Biol Chem 1988;263: 13152-8.
50. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994;269:5241-8.
51. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998;10:262-7.
52. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000;60:1383-7.
53. Humphrey PA, Wong AJ, Vogelstein B, Friedman HS, Werner MH, Bigner DD, Bigner SH. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 1988;48:2231-8.
54. Wennstrom S, Downward J. Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. Mol Cell Biol 1999;19:4279-88.
55. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88.
56. Maehama T, Dixon JE. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 1999;9:125-8.
57. Haaskogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D. Protein kinase B (PKB/AKT) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 1998;8:1195-8.
58. Soltoff SP, Carraway KL3, Prigent SA, Gullick WG, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994;14:3550-8.
59. Liu WG, James CD, Frederick L, Alderete BE, Jenkins RB. PTEN/ MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 1997;57:5254-7.
60. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002;62:200-7.